An open letter by the CEO of BioViva, Elizabeth Parrish, on the first anniversary of BioViva’s gene therapy against aging. One year ago today Elizabeth became the first person in the world to undergo a dual gene therapy treatment, specifically designed to treat biological aging.
Decades-old discovery about fetal hemoglobin may soon be cured using gene therapy. The clinical trial set to take place in the coming year
On the 20th of June, Elizabeth Parrish visited Moscow. As a result of the meeting an announcement was made with BioViva to open an outreach office in Russia. Additionally, an agreement to implement a crowd investing campaign for BioViva
We are gene therapy innovation leaders. We develop therapies to treat severe genetic disorders and cellular aging. We are working on several patents and are seeking strategic partnerships to help us make a positive step forward in our efforts to bring cures to aging populations and those who suffer monogenic disease.
At the heart of Bioviva's product creation efforts is its broadly applicable gene therapy platform for the development of novel one time treatments for diseases with either ineffective or no clinical options.
As well as investors we are seeking to engage the community to help us to make gene therapy the next revolution in medicine. If you are interested there is a lot you can do to help not just invest, we are seeking people to spread the word about our work, people to advocate for regenerative medicine, lobbying your government representatives and to push for gene therapy to be allowed. If you have a blog, write for a transhuman, longevity or regenerative medicine E-zine and would like to arrange an interview with us or join our circle of friends please get in touch, we would love to hear from you.